cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLC10.15829/1728-8800-2014-3-67-77cardiovascular-72Research ArticleМНЕНИЕ ПО ПРОБЛЕМЕOPINION ON A PROBLEMПАЦИЕНТ С АНЕМИЕЙ НА АМБУЛАТОРНОМ ПРИЁМЕANEMIC PATIENT AT GP’S OFFICEВёрткинА. Л.VertkinA. L.

д. м.н., профессор, заведующий кафедрой терапии, клинической фармакологии и СМП МГМСУ им. А. И. Евдокимова

edlaryushkina@gmail.comХовасоваН. О.KhovasovaN. O.

к. м.н., доцент кафедры терапии, клинической фармакологии и СМП МГМСУ им. А. И. Евдокимова

edlaryushkina@gmail.comЛарюшкинаЕ. Д.LaryushkinaE. D.

ассистент кафедры терапии, клинической фармакологии и СМП МГМСУ им. А. И. Евдокимова

edlaryushkina@gmail.comШамаеваК. И.ShamaevaK. I.

аспирант кафедры терапии, клинической фармакологии и СМП МГМСУ им. А. И. Евдокимова

edlaryushkina@gmail.comГБОУ ВПО Московский государственный медико-стоматологический университет им. А. И. Евдокимова, МоскваMoscow State Medico-Stomatological University n.a. Evdokimov A.I. Moscow, Russia2014200620141336777Copyright © Вёрткин А.Л., Ховасова Н.О., Ларюшкина Е.Д., Шамаева К.И., 20142014Вёрткин А.Л., Ховасова Н.О., Ларюшкина Е.Д., Шамаева К.И.Vertkin A.L., Khovasova N.O., Laryushkina E.D., Shamaeva K.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/72

Анемия в современной медицине — это не просто снижение гемоглобина, а фактор риска неблагоприятного исхода у сосудистых больных. При этом анемия зачастую не выставляется в клинический диагноз и не регистрируется в статистических отчетах. Анемия — это всегда осложнение и требует проведения диагностического алгоритма для выявления основного заболевания. На низкий уровень гемоглобина должен всегда обращать внимание участковый терапевт. На практике же это происходит лишь в 25% случаев. С учетом дефицита времени на амбулаторном приеме требуется алгоритмизация действий терапевта. В данной статье предложены алгоритмы ведения пациентов с выявленным сниженным уровнем гемоглобина.

In contemporary medicine anemia is not just a decrease of hemoglobin level, but risk factor for worse outcome in vascular patients. At the same time anemia usually is not stated in the diagnosis and is not registered in statistic reports. Anemia – is always a complication that is why it always requires diagnostic algorithm to explore the underlying reason. Low hemoglobin level must be always marked by general physician. However in practice this happens just in 25% cases. Due to time deficiency at outpatient visits there is a demand for algorithm to provide GP with. This article concerns such algorithms to investigate the patients with found low hemoglobin level.

анемияфакторы рискаамбулаторный приеммакроцитарная анемиямикроцитарная анемиянормоцитарная анемияanemiarisk factorsoutpatient visitmacrocytic anemiamicrocytic anemianormocytic anemiaReferencesFelker GM, Shaw LK, Stough WG, O’Connor CM. Am Heart J. 2006 Feb;151 (2):457–62.Felker GM, Shaw LK, Stough WG, O’Connor CM. Am Heart J. 2006 Feb;151 (2):457–62.Jankowska EA, Rozentryt P, Witkowska A, et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J 2010;31 (15):1872–80.Jankowska EA, Rozentryt P, Witkowska A, et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J 2010;31 (15):1872–80.Feinstein A. R. Pre-therapeutic classification of co-morbidity in chronic disease. Journal Chronic Disease 1970; 23 (7): 455–68.Feinstein A. R. Pre-therapeutic classification of co-morbidity in chronic disease. Journal Chronic Disease 1970; 23 (7): 455–68.Britt HC, Harrison CM, Miller GC, Knox SA. Prevalence and patterns of multimorbidity in Australia. MJA of Australia 2008; 189 (2): 72–7.Britt HC, Harrison CM, Miller GC, Knox SA. Prevalence and patterns of multimorbidity in Australia. MJA of Australia 2008; 189 (2): 72–7.Schoenberg NE, Kim H, Edwards W, Fleming ST. Burden of Common Multiple-Morbidity Constellations on Out-of-Pocket Medical Expenditures among Older Adults. Gerontologist 2007; 47, 4: 423–37.Schoenberg NE, Kim H, Edwards W, Fleming ST. Burden of Common Multiple-Morbidity Constellations on Out-of-Pocket Medical Expenditures among Older Adults. Gerontologist 2007; 47, 4: 423–37.Seeman TE, Guralnik JM, Kaplan GA, et al. The health consequences of multiple morbidity in the elderly: the Alameda County Study. J Aging Health 1989; 1: 50–66.Seeman TE, Guralnik JM, Kaplan GA, et al. The health consequences of multiple morbidity in the elderly: the Alameda County Study. J Aging Health 1989; 1: 50–66.Hematology: the Latest directory. Under the General Ed. K. M. Abdulkadyrova. Of Eksmo; SPb.: Publishing house Owl, 2004. S. Russian (Гематология: Новейший справочник. Под общ. ред. К. М. Абдулкадырова. Из-во Эксмо; СПб.: Изд-во Сова, 2004. 928с).Hematology: the Latest directory. Under the General Ed. K. M. Abdulkadyrova. Of Eksmo; SPb.: Publishing house Owl, 2004. S. Russian (Гематология: Новейший справочник. Под общ. ред. К. М. Абдулкадырова. Из-во Эксмо; СПб.: Изд-во Сова, 2004. 928с).Melnikova I. Anaemia therapies. Nat Rev Drug Discov 2006; 5: 627–8.Melnikova I. Anaemia therapies. Nat Rev Drug Discov 2006; 5: 627–8.Melis M, McLoughlin JM, Dean ЕМ. Correlations between neoadjuvant treatment, anemia, and perioperative complications in patients undergoing esophagectomy for cancer. J Surg Res 2009; 153: 114–20.Melis M, McLoughlin JM, Dean ЕМ. Correlations between neoadjuvant treatment, anemia, and perioperative complications in patients undergoing esophagectomy for cancer. J Surg Res 2009; 153: 114–20.Saravana S, Rai А. Anemia of chronic disease in patients with rheumatoid arthritisuse of zinc protoporphyrin (ZPP) levels. J Rheumatol 2007; 34: 446.Saravana S, Rai А. Anemia of chronic disease in patients with rheumatoid arthritisuse of zinc protoporphyrin (ZPP) levels. J Rheumatol 2007; 34: 446.Ruiz-Argьelles GJ, Dнaz-Hernбndez А, Manzano С. Ineffectiveness of oral iron hydroxide polymaltose in iron-deficiency anemia. Hematology 2007; 12: 255–6.Ruiz-Argьelles GJ, Dнaz-Hernбndez А, Manzano С. Ineffectiveness of oral iron hydroxide polymaltose in iron-deficiency anemia. Hematology 2007; 12: 255–6.Gouva С, Nikolopoulos Р, Ionnidis J, Siamopoulos К. Treating anemia early in renal failure patients slows the decline of renal funtion: a randomized controlled trial. Kidney Int 2004; 66: 753–60.Gouva С, Nikolopoulos Р, Ionnidis J, Siamopoulos К. Treating anemia early in renal failure patients slows the decline of renal funtion: a randomized controlled trial. Kidney Int 2004; 66: 753–60.Anand IS. Heart failure and anemia: mechanisms and pathophysiology. Heart 2008; 13: 379–86.Anand IS. Heart failure and anemia: mechanisms and pathophysiology. Heart 2008; 13: 379–86.Geisser P, Muller A. Iron pharmacokinitics of iron salts and ferric hydroxidecarbohydrate complexes. Drug Research 1987;37:100-4.Geisser P, Muller A. Iron pharmacokinitics of iron salts and ferric hydroxidecarbohydrate complexes. Drug Research 1987;37:100-4.Geisser P. Safety and Efficacy of Iron (III)-hydroxide Polymaltose Complex. A review of over 25 years of experience. Arzneimittel-Forschung (Drug Research) 2007; 57(6a):39–452.Geisser P. Safety and Efficacy of Iron (III)-hydroxide Polymaltose Complex. A review of over 25 years of experience. Arzneimittel-Forschung (Drug Research) 2007; 57(6a):39–452.Tobili JE, Brignoli R. Iron(III)-hydroxide Polymaltose Complex in Iron Deficiency Anemia. Arzneimittel-Forschung (Drug Research) 2007; 57(6a):431–8.Tobili JE, Brignoli R. Iron(III)-hydroxide Polymaltose Complex in Iron Deficiency Anemia. Arzneimittel-Forschung (Drug Research) 2007; 57(6a):431–8.Jacobs P, Fransman D, Coghlan P. Comparative bioavability of ferric carboxymaltose and ferrous sulphate in iron-deficient blood donors. J Clin Apher 1993: 8:89-95.Jacobs P, Fransman D, Coghlan P. Comparative bioavability of ferric carboxymaltose and ferrous sulphate in iron-deficient blood donors. J Clin Apher 1993: 8:89-95.Jaber L, Rigler S, Taya A, et al. Iron polymaltose versus ferrous gluconate in the prevention of iron deficiency anemia of infancy. J Pediatr Hematol Oncol. 2010 Nov; 32(8):585-8.Jaber L, Rigler S, Taya A, et al. Iron polymaltose versus ferrous gluconate in the prevention of iron deficiency anemia of infancy. J Pediatr Hematol Oncol. 2010 Nov; 32(8):585-8.Yasa B, Agaoglu L, Unuvar E. Efficacy, tolerability and acceptability of iron hydroxide polymaltose complex versus ferrous sulfate: a randomized trial in pediatric patients with iron deficiency anemia. Int. J. Pediatr. 2011: 524520. Epub 2011 Oct 31.Yasa B, Agaoglu L, Unuvar E. Efficacy, tolerability and acceptability of iron hydroxide polymaltose complex versus ferrous sulfate: a randomized trial in pediatric patients with iron deficiency anemia. Int. J. Pediatr. 2011: 524520. Epub 2011 Oct 31.Walter T, Zacarias I, Yanez CG. Tolerance and acceptability in infants of iron polymaltose complex. Ars Medici 2005; 9:428-31.Walter T, Zacarias I, Yanez CG. Tolerance and acceptability in infants of iron polymaltose complex. Ars Medici 2005; 9:428-31.Инструкция по медицинскому применению препарата “Феррум Лек”. http://www.vidal.ru/drugs/ferrum_lek~23506.Инструкция по медицинскому применению препарата “Феррум Лек”. http://www.vidal.ru/drugs/ferrum_lek~23506.Ylmaz S, Uсar A. A review of the genotoxic and carcinogenic effects of aspartame: does it safe or not? Cytotechnology 2014. DOI 10.1007/s10616-013-9681-0.Ylmaz S, Uсar A. A review of the genotoxic and carcinogenic effects of aspartame: does it safe or not? Cytotechnology 2014. DOI 10.1007/s10616-013-9681-0.Anker S.D, Comin-Colet J, Filippatos G. Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency. N Engl J Med 2009; 361:2436-48.Anker S.D, Comin-Colet J, Filippatos G. Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency. N Engl J Med 2009; 361:2436-48.

The authors declare that there are no conflicts of interest present.